2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

antibody-conjugate

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

5

Fluorescent Dye

2

Biochemical Assay Reagents

2

Inhibitory Antibodies

2

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19318
    Fmoc-Val-Cit-PAB

    		ADC Linker Cancer
    Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.
    Fmoc-Val-Cit-PAB
  • HY-145767A
    SN-38-CO-DMEDA TFA

    		Drug Intermediate Others
    SN-38-CO-DMEDA TFA is the intermediate product for synthesizing antibody-conjugated drug LND1035 .
    SN-38-CO-DMEDA TFA
  • HY-102001
    Tomaymycin DM

    		ADC Payload Cancer
    Tomaymycin DM is a tomaymycin derivative, PBD monomer, and DNA alkylating agent. Tomaymycin DM can serve as a payload in tumor-targeting antibody-conjugated active molecules (ADCs).
    Tomaymycin DM
  • HY-169322
    APL-1081

    Mal-Exo-EVC-MMAE

    		 Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    APL-1081 (Mal-Exo-EVC-MMAE) is part of an antibody-conjugated active molecule (ADC). APL-1081 is conjugated with an ADC linker (peptide Mal-Exo-EEVC) and a potent tubulin polymerization inhibitor, MMAE (HY-15162) .
    APL-1081
  • HY-W426106
    Gly-NH-CH2-Boc

    		ADC Linker Cancer
    Gly-NH-CH2-Boc is a cleavable ADC linker that can be used to synthesize antibody-conjugated active molecules (ADC) .
    Gly-NH-CH2-Boc
  • HY-19318G
    Fmoc-Val-Cit-PAB

    		ADC Linker Cancer
    Fmoc-Val-Cit-PAB GMP is a GMP grade Fmoc-Val-Cit-PAB (HY-19318). Fmoc-Val-Cit-PAB is a cleavable antibody-conjugated active molecule (ADC) commonly used linker.
    Fmoc-Val-Cit-PAB
  • HY-153196
    Tetra-O-acetyl-β-D-galactopyranosyl-Ph-CH2-(4-nitrophenyl)carbonate-Fmoc

    		ADC Linker Others
    Tetra-O-acetyl-β-D-galactopyranosyl-Ph-CH2-(4-nitrophenyl)carbonate-Fmoc (Example 2.28.6) is an ADC linker that can be used to synthesize antibody-conjugated active molecules (ADCs) .
    Tetra-O-acetyl-β-D-galactopyranosyl-Ph-CH2-(4-nitrophenyl)carbonate-Fmoc
  • HY-171792
    BMS-986497

    ORM-6151

    		 Transmembrane Glycoprotein Cancer
    BMS-986497 (ORM-6151) is a CD33-targeted antibody-conjugated GSPT1 degrader. BMS-986497 delivers the GSPT1 degrader SMol006 to CD33-expressing cells, inducing GSPT1 protein degradation. BMS-986497 is promising for research of acute myeloid leukemia (AML) .
    BMS-986497
  • HY-164146
    BCN-HS-PEG2(vcPABC-MMAE)2

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Cancer
    BCN-HS-PEG2(vcPABC-MMAE)2 is a drug-linker conjugate for ADC consists an ADC linker and a tubulin polymerization inhibitor MMAE (HY-15162). BCN-HS-PEG2(vcPABC-MMAE)2 can be used in the synthesis of antibody-agent conjugates (ADCs) .
    BCN-HS-PEG2(vcPABC-MMAE)2
  • HY-150075
    STING agonist-19

    		STING Others
    STING agonist-19 can be used to synthesize ISAC (immune-stimulating antibody conjugates) molecule.
    STING agonist-19
  • HY-159665
    CDLI-5

    		E3 Ligase Ligand-Linker Conjugates Cancer
    CDLI-5 is a cereblon degrader-linker conjugate, and can be used for synthesis of cereblon degrader antibody conjugates (cDACs) .
    CDLI-5
  • HY-145620
    Zuvotolimod

    		ADC Linker Inflammation/Immunology Cancer
    Zuvotolimod is a myeloid cell agonist compound-linker for antibody conjugate. Zuvotolimod can be used in the research of cancer and hepatitis .
    Zuvotolimod
  • HY-165164
    Methotrexate-alpha-alanine

    		Others Cancer
    Methotrexate-alpha-alanine is a prodrug for activation by enzyme-monoclonal antibody conjugates. Methotrexate-alpha-alanine shows cytotoxicity .
    Methotrexate-alpha-alanine
  • HY-112901
    DC41

    		ADC Payload Cancer
    DC41 is a DC1 derivative. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer .
    DC41
  • HY-D1546
    Biotin-C2-maleimide

    		Fluorescent Dye Cancer
    Biotin-C2-maleimide is an antibody conjugate reagent, can bind to many biomolecules without significantly changing the biological activity of the target molecule .
    Biotin-C2-maleimide
  • HY-128871
    VCP-Eribulin

    		Drug-Linker Conjugates for ADC Cancer
    VCP-Eribulin consists the ADCs linker (VCP) and Eribulin . Eribulin is a mechanistically unique microtubule inhibitor for cancer . VCP-Eribulin is an Eribulin-based agent for antibody conjugates .
    VCP-Eribulin
  • HY-126668A
    Mal-PEG4-VC-PAB-DMEA TFA

    		ADC Linker Cancer
    Mal-PEG4-VC-PAB-DMEA TFA is a degradable ADC linker containing a maleimide group and can be used to synthesize antibody conjugate active molecules (ADCs) .
    Mal-PEG4-VC-PAB-DMEA TFA
  • HY-161022A
    FL118-C3-O-C-amide-C-NH2 formate

    		ADC Linker Cancer
    FL118-C3-O-C-amide-C-NH2 format is an ADC linker for the synthesis of synthetic antibody conjugate active molecules (ADCs)..
    FL118-C3-O-C-amide-C-NH2 formate
  • HY-156693
    MTvkPABC-P5

    		Toll-like Receptor (TLR) Inflammation/Immunology
    MTvkPABC-P5d, a TLR7 agonist, is an immune stimulant. MTvkPABC-P5d can be used for synthesis of immune-stimulating antibody conjugates (ISACs) .
    MTvkPABC-P5
  • HY-148127
    TAM558

    		Drug-Linker Conjugates for ADC Cancer
    TAM558 is a payload molecule used for the synthesis of OMTX705. OMTX705 is a humanized anti-fibroblast-activating protein (FAP) antibody conjugated to the cytolysin TAM470 (HY-148128), with antitumor activity .
    TAM558
  • HY-156693A
    MTvkPABC-P5 TFA

    		Toll-like Receptor (TLR) Inflammation/Immunology
    MTvkPABC-P5d TFA, a TLR7 agonist, is an immune stimulant. MTvkPABC-P5d TFA can be used for synthesis of immune-stimulating antibody conjugates (ISACs) .
    MTvkPABC-P5 TFA
  • HY-176774
    L07-2

    		Toll-like Receptor (TLR) Cancer
    L07-2 (Compound 6) is an active scaffold comprising a stimulator of TLR7/8. L07-2 can be used for synthesis of immune-stimulating antibody conjugates (ISACs) for cancers research .
    L07-2
  • HY-19792
    Mertansine
    Maximum Cited Publications
    25 Publications Verification

    DM1; Maytansinoid DM1

    		 Microtubule/Tubulin ADC Payload Cancer
    Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. Mertansine can be attached to a monoclonal antibody with a linker to create an antibody-drug conjugate (ADC) .
    Mertansine
  • HY-164734
    Raludotatug Deruxtecan

    R-DXd; DS-6000

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Raludotatug Deruxtecan (DS-6000) is a novel antibody conjugate (ADC) targeting CDH6. Raludotatug Deruxtecan is conjugated with Raludotatug (HY-P990028) and Deruxtecan (HY-13631E). Raludotatug Deruxtecan can be used in the research of ovarian cancer and renal cancer.
    Raludotatug Deruxtecan
  • HY-13631F
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan, as a drug-linker conjugate composed of linker Gly-Gly-Phe-Gly-NH-O-CO and Exatecan, can be used to prepare antibody conjugate drugs. Exatecan is a DNA topoisomerase I inhibitor that can be used in cancer research .
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride
  • HY-112900
    DC41SMe

    		ADC Payload Cancer
    DC41SMe, a DC1 derivative, shows cytotoxicity in Ramos, Namalwa, and HL60/s cells with IC50s ranging from 18-25 pM. DC1, a simplified analogue of CC-1065, is an antibody conjugate of cytotoxic DNA alkylators for the targeted treatment of cancer .
    DC41SMe
  • HY-147215
    UC-1V150

    		Toll-like Receptor (TLR) Inflammation/Immunology
    UC-1V150 is a specific TLR7 (Toll-like receptor) agonist that stimulates cellular immune responses and has anti-tumor activity. UC-1V150 can be used to synthesize ISAC (Immune-Stimulating Antibody Conjugates) molecule .
    UC-1V150
  • HY-114233
    MC-GGFG-Exatecan
    5+ Cited Publications

    MC-GGFG-DX8951

    		 Drug-Linker Conjugates for ADC Topoisomerase Cancer
    MC-GGFG-Exatecan (MC-GGFG-DX8951) is a agent-linker conjugate for ADC. MC-GGFG-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with protease cleavable MC-GGFG linker. MC-GGFG-Exatecan shows antitumor activity and can be used to prepare DX8951 antibody conjugate (ADC) .
    MC-GGFG-Exatecan
  • HY-141606
    Anetumab ravtansine

    BAY 94-9343

    		 Microtubule/Tubulin Antibody-Drug Conjugates (ADCs) Cancer
    Anetumab ravtansine (BAY 94-9343) is a selective and highly potent antibody-drug conjugate (ADC) to target maytansinoid tubulin. Anetumab ravtansine consists of a human anti-mesothelin antibody conjugated to the maytansinoid tubulin inhibitor DM4. Anetumab ravtansine shows antitumor efficacy correlated with the amount of mesothelin expressed in patient-derived xenograft tumor models .
    Anetumab ravtansine
  • HY-147236
    TLR7/8 agonist 7

    		Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7/8 agonist 7 (compound 10) is a TLR7/8 agonist. TLR7/8 agonist 7 activates a variety of immune cells and it can be used to synthesize immune stimulating antibody conjugate (ISAC) molecules. TLR7/8 agonist 7 can be used for the research of immunity .
    TLR7/8 agonist 7
  • HY-150233
    Cys-McMMAF

    		Microtubule/Tubulin Cancer
    Cys-McMMAF is the released payload of AlMcMMAF, an anti-5T4 humanized A1 antibody conjugated to the microtubule disrupting MMAF (HY-15579) via a maleimidocaproyl linker. Cys-McMMAF has antitumor efficacy in two tumor mouse models (H1975 and MDA-MB-361-DYT2 models) .
    Cys-McMMAF
  • HY-128870
    Mal-PEG2-VCP-Eribulin

    		Drug-Linker Conjugates for ADC Cancer
    Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin (HY-13442). Eribulin is a mechanistically unique microtubule inhibitor and Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules. Mal-PEG2-VCP-Eribulin is an Eribulin-based agent for antibody conjugates .
    Mal-PEG2-VCP-Eribulin
  • HY-129937
    (S)-GNE-987

    		PROTACs Epigenetic Reader Domain Cancer
    (S)-GNE-987 (compound 4), the GNE-987 (a chimeric BET degrader) hydroxy-proline epimer, abrogates binding to von Hippel-Lindau and does not degrade BRD4 protein. (S)-GNE-987 binds to the BRD4 BD1(IC50=4 nM) and BD2 (3.9 nM) bromodomains and can be used to design PROTAC-Antibody Conjugate (PAC) .
    (S)-GNE-987
  • HY-171821
    PF-08046054

    SGN-PDL1V

    		 Antibody-Drug Conjugates (ADCs) PD-1/PD-L1 Microtubule/Tubulin Cancer
    PF-08046054 (SGN-PDL1V) is a PD-L1-directed antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to the vedotin drug-linker, VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors .
    PF-08046054
  • HY-P2149A
    Concanavalin A (agarose)

    		Biochemical Assay Reagents Others
    Concanavalin A (agarose) consists of Concanavalin A (HY-P2149) coupled to agarose. Concanavalin A is a tetrameric metalloprotein lectin isolated from Canavalia ensiformis (jack bean). Concanavalin A (agarose) is used for the purification of glycoproteins, polysaccharides and glycolipids as it binds molecules containing α-D-mannopyranosyl, α-D-glucopyranosyl and sterically related residues. Concanavalin A (agarose) has also be used in other application areas including purification of enzyme-antibody conjugates, purification of IgM and separation of membrane vesicles .
    Concanavalin A (agarose)
  • HY-164995
    L1BC8

    		PROTACs Epigenetic Reader Domain Drug-Linker Conjugates for ADC Cancer
    L1BC8 (compound 13a) is a BRD4 PROTAC degrader with anticancer effects. L1BC8 is also a drug-linker conjugate for ADC that can be used for the synthesis of ADCs. The resulting BRD4-degrader antibody conjugates exhibit potent and antigen-dependent BRD4 degradation and antiproliferation activities in cell-based experiments. (Pink: BRD4 ligand (HY-129939); Blue: VHL ligand (HY-125845); Black: linker (HY-171663)) .
    L1BC8
  • HY-P99016A
    Enfortumab vedotin-ejfv

    		Antibody-Drug Conjugates (ADCs) Nectin-4 Cancer
    Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
    Enfortumab vedotin-ejfv
  • HY-136261
    DM1-PEG4-DBCO

    		Drug-Linker Conjugates for ADC Cancer
    DM1-(PEG)4-DBCO is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DM1-PEG4-DBCO is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DM1-PEG4-DBCO
  • HY-P99016B
    Enfortumab vedotin-ejfv (solution)

    		Antibody-Drug Conjugates (ADCs) Nectin-4 Cancer
    Enfortumab vedotin-ejfv (solution) is an anti-Nectin-4 antibody-drug conjugate (ADC). Enfortumab vedotin-ejfv (solution) is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable Val-Cit linker. The antibody portion is Enfortumab (HY-P99016), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv (solution) is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma .
    Enfortumab vedotin-ejfv (solution)
  • HY-136260
    DBCO-PEG4-Ahx-DM1

    		Drug-Linker Conjugates for ADC Cancer
    DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-Ahx-DM1
  • HY-148346
    STING agonist-20-Ala-amide-PEG2-C2-NH2

    		Drug-Linker Conjugates for ADC STING Cancer
    STING agonist-20-Ala-amide-PEG2-C2-NH2 is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 can be used for the research of cancer .
    STING agonist-20-Ala-amide-PEG2-C2-NH2
  • HY-129937A
    GNE-987
    1 Publications Verification

    		 PROTACs Epigenetic Reader Domain Cancer
    GNE-987 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. GNE-987 exhibits picomolar cell BRD4 degradation activity (DC50=0.03 nM for EOL-1 AML cell line). GNE-987 binds equipotently to the BD1 and BD2 bromodomains of BRD4 with low nanomolar affinities (IC50=4.7 and 4.4 nM, respectively). GNE-987 incorporates a potent BET binder/inhibitor, a VHL-binding fragment, and a ten methylene spacer moiety. GNE-987 can be used in PROTAC-Antibody Conjugate (PAC) .
    GNE-987
  • HY-148346A
    STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA

    		Drug-Linker Conjugates for ADC STING Cancer
    STING agonist-20-Ala-amide-PEG2-C2-NH2 (Compound 30b) TFA is an active scaffold comprising a stimulator of interferon genes (STING). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used to synthesize immune-stimulating antibody conjugate (ISAC). STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA can be used for the research of cancer .
    STING agonist-20-Ala-amide-PEG2-C2-NH2 TFA
  • HY-153360
    MC-GGFG-AM-(10Me-11F-Camptothecin)

    		Drug-Linker Conjugates for ADC Topoisomerase Cancer
    MC-GGFG-AM-(10Me-11F-Camptothecin) is a linker-payload conjugate used to synthesize ZW251. ZW251 an antibody-drug conjugate (ADC) targeting human GPC3. ZW251 consists of a humanized IgG1 antibody conjugated to a novel camptothecin-based topoisomerase 1 inhibitor, ZD06519, via a linker. The linker is the maleimide anchor and a glycyl glycyl phenylalanyl glycine (GGFG)-aminomethyl (AM) cleavable linker. ZW251 has high affinity with human and cynomolgus monkey GPC3. ZW251 displays rapid internalization in GPC3-expressing HCC cell lines, and bystander-mediated killing of GPC3 negative cancer cells .
    MC-GGFG-AM-(10Me-11F-Camptothecin)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: